Obstetrics

 
 APOSTEL VIII
 
 Dutch TRUFFLE
 
 2Close
 
 APRIL
 Highlow
 
 PC
 Quadruple P
 
 SIMPLE III
 
 Stop or Go?
 
 STRIDER
 
 SUGAR-DIP
 
 KEUZEHULP IMPLEMENTATIE
 
 INDEX
 MOTHER
 NethOSS
 Ppromexil-III
 ALLO
 AMPHIA
 APOSTEL-I
 APOSTEL-II
 APOSTEL-III
 APOSTEL-IV
 
 Apostel VI
 ASB
 CHIPS
 DIGITAT
 ECV Implementation
 EuFis
 Fluxim
 GlucoMOMS
 HTA Longterm conseq.
 HTA Preference study
 HYPITAT
 HYPITAT-II
 HyRAS (Hypitat followup)
 Implementatie Tour
 IUPC
 PIMPP
 PPROMCerclage
 PPROMEXIL
 PreCare
 PROBAAT
 PROBAAT-II
 PROBAAT-S
 ProTWIN
 SimpleII
 STAN
 TeMpOH-1
 TeMpOH-3
 TOSTI
 TOTEM
 Triple P
 TRUFFLE
 WOMB study

 ABCD-study
 BIG CHANGE
 CAMPUR
 Cancer in pregnancy
 Doula study
 ECV tocolysis
 ECV Uterine relaxation
 EuroHeartSurvey
 > FRUIT
 HP4ALL-PC
 HP4ALL-RS
 IMPACT
 INCAS
 IRIS
 Keizerlijk litteken
 MAKE
 OOPUS
 PRELHUDE
 PROMISES
 RAVEL
 SIMPLE
 STAN followup
 VET study
 VIS-project
 Wat bevalt beter
 ZAHARA II
 ZAHARA 3
 ZOBASII
 

FRUIT

Low molecular weightheparin (Fragmin) in pregnant women with a history of uteroplacentalinsufficiency and thrombophilia, a randomized trial

See also FRUIT study on the NVOG website

Aim of the study
Primary: Does preventive treatment with low-molecular-weight heparinreduce the occurrence of preeclampsia in women with thrombophilia and ahistory of preeclampsia before 34 weeks of pregnancy.
Secondary: A reduction of recurrence of small for gestational ageinfants in women with a history of small for gestational age infantsbefore 34 weeks and thrombophilia.

Trial
Multi-center open two-armed randomized study.

Population
The recurrence rate of preeclampsia is 35% and small for gestationalage infants 21% as recently studied in a Dutch population with a priorpregnancy with severe early onset preeclampsia or small for gestationalage infants (before 34 weeks gestation) and coagulation abnormalities,being treated with or without low-molecular-weight heparin and aspirin.
To detect a 50% reduction from 35% recurrence rate of preeclampsia 262patients will be randomized, aiming for 131 + 131 patients in the 2arms of the study (2-tailed, an alpha of 0.05 and a power of 80%).Recurrence rate of uteroplacental insufficiency in women withantiphospholipid antibodies is 60%. To detect a 50% reduction from 60%recurrence rate of uteroplacental insufficiency 84 patients will berandomized, aiming for 42 + 42 patients in the 2 arms of the study(2-tailed, an alpha of 0.05 and a power of 80%).

Intervention
The verum group will receive low-molecular weight heparin (Fragmin,subcutaneously 1 x 5000 IU AXA per day) + low dose acetylsalicylacid(ASA 80mg). Fragmin is started as early as possible between six andtwelve weeks gestation, after ultrasound confirmation of a viableintrauterine pregnancy. Fragmin will be continued until six weeks postpartum. ASA is given from 12 weeks gestation till 36 weeks gestation.The control group will receive ASA and standard care that is normallygiven to these high-risk pregnancies.

Analysis
Differences between the groups treated with low-molecular weightheparin and aspirin versus aspirin only will be assessed, accountingfor prognostic factors, with the Mantel-Haenszel method or withlogistic regression. Quantitative analysis will be assessed with linearregression.


Download here the FRUIT protocol - version 20-01-2000.


Other documents: